tert-butyl [(2S)-1-(4-fluorophenyl)-1-oxopropan-2-yl]carbamate | 357926-96-6

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: tert-butyl [(2S)-1-(4-fluorophenyl)-1-oxopropan-2-yl]carbamate
• 英文别名: t-butyl N-[(1S)-2-(4-fluorophenyl)-1-methyl-2-oxoethyl]carbamate；tert-butyl N-[(2S)-1-(4-fluorophenyl)-1-oxopropan-2-yl]carbamate
• CAS: 357926-96-6
• 化学式: C₁₄H₁₈FNO₃
• 分子量: 267.3
• InChiKey: OZFLADPELOCPRG-VIFPVBQESA-N

物化性质

• 沸点：
  389.7±22.0 °C(Predicted)
• 密度：
  1.128±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  19
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.43
• 拓扑面积：
  55.4
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  tert-butyl [(2S)-1-(4-fluorophenyl)-1-oxopropan-2-yl]carbamate 在 盐酸 、 盐酸羟胺 、 sodium acetate 、 三乙胺 作用下， 以 四氢呋喃 、 乙醇 、 乙酸乙酯 、 甲苯 为溶剂， 反应 4.5h， 生成 (2S)-1-[(diphenylphosphinoyl)amino]-1,1-bis(4-fluorophenyl)-2-propylamine
  参考文献：
  名称：

  光学活性三取代的1,2-乙二胺的高立体选择性合成：格氏加成反应衍生自氨基酸的N-二苯基膦酰基酮亚胺的第一个实例

  摘要：

  描述了光学活性的三取代的1,2-亚乙基二胺的有效合成。已证明将芳基和/或烷基格氏试剂添加到衍生自α-氨基酸的α-氨基N-二苯基膦酰基酮亚胺中，可以以良好的收率和高的非对映选择性提供所需的三取代的1,2-乙二胺。随后在新开发的还原条件下，以合理的收率顺利完成了从加合物中除去二苯膦酰基的合成，而没有外消旋作用。

  DOI：

  10.1021/jo049405i
• 作为产物：
  描述：

  N-叔丁氧羰基-L-丙氨酸 在 1-羟基苯并三唑 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 、 三乙胺 作用下， 以 四氢呋喃 、 N,N-二甲基甲酰胺 为溶剂， 反应 36.0h， 生成 tert-butyl [(2S)-1-(4-fluorophenyl)-1-oxopropan-2-yl]carbamate
  参考文献：
  名称：

  Discovery of 3,5-Diphenyl-4-methyl-1,3-oxazolidin-2-ones as Novel, Potent, and Orally Available Δ-5 Desaturase (D5D) Inhibitors

  摘要：

  The discovery and optimization of Delta-5 desaturase (D5D) inhibitors are described. Investigation of the 1,3-oxazolidin-2-one scaffold was inspired by a pharmacophore model constructed from the common features of several hit compounds, resulting in the identification of 3,5-diphenyl-1,3-oxazolidin-2-one Sh as a novel lead showing potent in vitro activity. Subsequent optimization focused on the modification of two metabolic sites, which provided (4S,5S)-5i, a derivative with improved metabolic stability. Moreover, adding a substituent into the upper phenyl moiety further enhanced the intrinsic activity, which led to the discovery of 5-[(4S,5S)-5-(4fluorophenyl)-4-methyl-2-oxo-1,3-oxazolidin-3-yl]benzene-1,3-clicarbonitrile (4S,5S)-5n, endowed with excellent DSD binding affinity, cellular activity, and high oral bioavailability in a mouse. It exhibited robust in vivo hepatic arachidonic acid/dihomo-gamma-linolenic acid ratio reduction (a target engagement marker) in an atherosclerosis mouse model. Finally, an asymmetric synthetic procedure for this compound was established.

  DOI：

  10.1021/acs.jmedchem.7b01210

文献信息

• Novel imidazonline compounds
  申请人：——

  公开号：US20030158418A1

  公开（公告）日：2003-08-21

  Compounds represented by the general formula (I): 1 wherein Ar 1 and Ar 2 are each aryl or heteroaryl; R 1 is lower cycloalkyl, —Ar 3 , or a group of the general formula (a), (b) or (c): 2 and R 2 and R 3 are each hydrogen, lower cycloalkyl, lower alkenyl, or optionally substituted lower alkyl (with the proviso that when R 2 and R 3 are simultaneously hydrogen, Ar 1 , Ar 2 and R 1 do not simultaneously represent unsubstituted phenyl). The compounds are useful as treating agents for various NPY-related diseases, for example, circulatory diseases including hypertension, kidney diseases, cardiac diseases, vasospasm and arteriosclerosis; central nervous system diseases including hyperphagia, depression, anxiety, convulsion, epilepsy, dementia, pain, alcohol dependence, and withdrawal symptoms due to abstinence from drugs; metabolic diseases including obesity, diabetes, hormonal disorders, hypercholesterolemia, and hyperlipidemia; sexual dysfunction and reproductive function disorders; digestive diseases including enterokinetic disorders; respiratory diseases; inflammation; or glaucoma.

  化合物的一般公式(I)代表的化合物，其中Ar1和Ar2分别为芳香族或杂环芳基；R1为较低的环烷基，-Ar3，或一般公式(a)，(b)或(c)的基团；R2和R3分别为氢、较低的环烷基、较低的烯基，或可选择地取代的较低烷基（但当R2和R3同时为氢时，Ar1、Ar2和R1不同时代表未取代的苯基）。这些化合物可用作治疗各种NPY相关疾病的药物，例如循环系统疾病包括高血压、肾脏疾病、心脏疾病、血管痉挛和动脉硬化；中枢神经系统疾病包括过食、抑郁、焦虑、抽搐、癫痫、痴呆、疼痛、酒精依赖以及因戒断药物而引起的戒断症状；代谢性疾病包括肥胖、糖尿病、激素紊乱、高胆固醇血症和高脂血症；性功能障碍和生殖功能障碍；消化系统疾病包括肠动力失调；呼吸系统疾病；炎症；或青光眼。
• Novel imidazoline compounds
  申请人：Sato Nagaaki

  公开号：US20060135559A1

  公开（公告）日：2006-06-22

  Compounds represented by the general formula (I): wherein Ar 1 and Ar 2 are each aryl or heteroaryl; R 1 is lower cycloalkyl, —Ar 3 , or a group of the general formula (a), (b) or (c): and R 2 and R 3 are each hydrogen, lower cycloalkyl, lower alkenyl, or optionally substituted lower alkyl (with the proviso that when R 2 and R 3 are simultaneously hydrogen, Ar 1 , Ar 2 and R 1 do not simultaneously represent unsubstituted phenyl). The compounds are useful as treating agents for various NPY-related diseases, for example, circulatory diseases including hypertension, kidney diseases, cardiac diseases, vasospasm and arteriosclerosis; central nervous system diseases including hyperphagia, depression, anxiety, convulsion, epilepsy, dementia, pain, alcohol dependence, and withdrawal symptoms due to abstinence from drugs; metabolic diseases including obesity, diabetes, hormonal disorders, hypercholesterolemia, and hyperlipidemia; sexual dysfunction and reproductive function disorders; digestive diseases including enterokinetic disorders; respiratory diseases; inflammation; or glaucoma.

  化合物的通式(I)表示为：其中Ar1和Ar2均为芳基或杂环芳基；R1为较低的环烷基，-Ar3，或通式(a)、(b)或(c)的一种基团：而R2和R3均为氢、较低的环烷基、较低的烯基或可选取代的较低烷基（前提是当R2和R3同时为氢时，Ar1、Ar2和R1不同时表示未取代的苯基）。这些化合物可用作治疗各种NPY相关疾病的治疗剂，例如循环系统疾病，包括高血压、肾脏疾病、心脏疾病、血管痉挛和动脉硬化；中枢神经系统疾病，包括过度进食、抑郁症、焦虑症、惊厥、癫痫、痴呆、疼痛、酒精依赖和戒断症状；代谢性疾病，包括肥胖、糖尿病、内分泌失调、高胆固醇血症和高脂血症；性功能障碍和生殖功能障碍；消化系统疾病，包括肠动力失调；呼吸系统疾病；炎症；或青光眼。
• Novel pyridone derivatives
  申请人：Sato Nagaaki

  公开号：US20050154025A1

  公开（公告）日：2005-07-14

  A compound of the formula (I): wherein R 1 is hydrogen, halogen, cyano, lower alkyl, halo-lower alkyl, hydroxy, lower alkoxy or aralkyloxy; R 2 and R 3 are each independently hydrogen, halogen or halo-lower alkyl; and R 4 and R are each independently hydrogen or halogen, is useful as a pharmaceutical composition for the treatment of various diseases related to NPY, for example, cardiovascular disorders such as angina, acute or congestive heart failure, myocardial infarction, hypertension, nephropathy, electrolyte abnormality, vasospasm, etc., nervous system disorders such as bulimia, depression, anxiety, seizure, epilepsy, dementia, pain, alcoholism, drug withdrawal, circadian rhythm disorders, schizophrenia, memory impairment, sleep disorders, cognitive impairment, etc., metabolic diseases such as obesity, diabetes, hormone abnormality, gout, fatty liver, etc., genital or reproductive disorders such as infertility, preterm labor, sexual dysfunction, etc., gastro-intestinal disorders, respiratory disorders, inflammatory diseases or glaucoma, and the like.

  式(I)的化合物：其中R1为氢、卤、氰、低碳基、卤代低碳基、羟基、低烷氧基或芳基氧基；R2和R3各自独立地为氢、卤或卤代低碳基；R4和R各自独立地为氢或卤。该化合物可用作药物组合物，用于治疗与NPY相关的各种疾病，例如心血管疾病（如心绞痛、急性或充血性心力衰竭、心肌梗死、高血压、肾病、电解质异常、血管痉挛等）、神经系统疾病（如贪食症、抑郁症、焦虑症、癫痫、失智症、疼痛、酗酒、戒毒、昼夜节律紊乱、精神分裂症、记忆障碍、睡眠障碍、认知障碍等）、代谢性疾病（如肥胖症、糖尿病、激素异常、痛风、脂肪肝等）、生殖系统疾病（如不孕症、早产、性功能障碍等）、胃肠道疾病、呼吸系统疾病、炎症性疾病或青光眼等。
• Pyridone derivatives
  申请人：Banyu Pharmaceutical Co., Ltd.

  公开号：US07119107B2

  公开（公告）日：2006-10-10

  A compound of the formula (I): wherein R1 is hydrogen, halogen, cyano, lower alkyl, halo-lower alkyl, hydroxy, lower alkoxy or aralkyloxy; R2 and R3 are each independently hydrogen, halogen or halo-lower alkyl; and R4 and R5 are each independently hydrogen or halogen, is useful as a pharmaceutical composition for the treatment of various diseases related to NPY, for example, cardiovascular disorders such as angina, acute or congestive heart failure, myocardial infarction, hypertension, nephropathy, electrolyte abnormality, vasospasm, etc., nervous system disorders such as bulimia, depression, anxiety, seizure, epilepsy, dementia, pain, alcoholism, drug withdrawal, circadian rhythm disorders, schizophrenia, memory impairment, sleep disorders, cognitive impairment, etc., metabolic diseases such as obesity, diabetes, hormone abnormality, gout, fatty liver, etc., genital or reproductive disorders such as infertility, preterm labor, sexual dysfunction, etc., gastro-intestinal disorders, respiratory disorders, inflammatory diseases or glaucoma, and the like.

  化合物的式子为（I）：其中，R1为氢、卤素、氰基、低碳基、卤代低碳基、羟基、低烷氧基或芳基甲氧基；R2和R3各自独立地为氢、卤素或卤代低碳基；R4和R5各自独立地为氢或卤素。这种化合物可用作制备药物组合物，用于治疗与NPY相关的各种疾病，例如心血管疾病（如心绞痛、急性或充血性心力衰竭、心肌梗死、高血压、肾病、电解质异常、血管痉挛等）、神经系统疾病（如贪食症、抑郁症、焦虑症、癫痫、痴呆、疼痛、酗酒、戒毒、生物钟失调疾病、精神分裂症、记忆障碍、睡眠障碍、认知障碍等）、代谢性疾病（如肥胖症、糖尿病、激素异常、痛风、脂肪肝等）、生殖系统或生殖障碍（如不孕症、早产、性功能障碍等）、胃肠道疾病、呼吸系统疾病、炎症性疾病或青光眼等。
• Imidazoline compounds
  申请人：Banyu Pharmaceutical Co., Ltd.

  公开号：US07482358B2

  公开（公告）日：2009-01-27

  Compounds represented by the general formula (I): wherein Ar1 and Ar2 are each aryl or heteroaryl; R1 is lower cycloalkyl, —Ar3, or a group of the general formula (a), (b) or (c): and R2 and R3are each hydrogen, lower cycloalkyl, lower alkenyl, or optionally substituted lower alkyl (with the proviso that when R2 and R3 are simultaneously hydrogen, Ar1, Ar2 and R1 do not simultaneously represent unsubstituted phenyl). The compounds are useful as treating agents for various NPY-related diseases, for example, circulatory diseases including hypertension, kidney diseases, cardiac diseases, vasospasm and arteriosclerosis; central nervous system diseases including hyperphagia, depression, anxiety, convulsion, epilepsy, dementia, pain, alcohol dependence, and withdrawal symptoms due to abstinence from drugs; metabolic diseases including obesity, diabetes, hormonal disorders, hypercholesterolemia, and hyperlipidemia; sexual dysfunction and reproductive function disorders; digestive diseases including enterokinetic disorders; respiratory diseases; inflammation; or glaucoma.

  通式（I）所表示的化合物，其中Ar1和Ar2分别为芳基或杂环芳基；R1为低环烷基，-Ar3，或通式（a），（b）或（c）的一般式中的基团：R2和R3分别为氢，低环烷基，低烯基或可选择取代的低烷基（条件是当R2和R3同时为氢时，Ar1，Ar2和R1不同时表示未取代的苯基）。该化合物可用作治疗各种NPY相关疾病的药剂，例如循环系统疾病，包括高血压，肾脏疾病，心脏疾病，血管痉挛和动脉硬化；中枢神经系统疾病，包括暴饮暴食，抑郁症，焦虑症，惊厥，癫痫，痴呆，疼痛，酒精依赖和戒断症状；代谢性疾病，包括肥胖症，糖尿病，激素失调，高胆固醇血症和高脂血症；性功能障碍和生殖功能障碍；消化系统疾病，包括肠动力失调；呼吸系统疾病；炎症；或青光眼。